Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma

@article{Ahles2004QualityOL,
  title={Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma},
  author={T. Ahles and J. Herndon and E. Small and N. Vogelzang and A. Kornblith and M. Ratain and W. Stadler and David Palchak and M. Marshall and G. Wilding and D. Petrylak and J. Holland},
  journal={Cancer},
  year={2004},
  volume={101}
}
Research has suggested that men with hormone‐refractory prostate carcinoma have a lower quality of life (QOL) compared with men who have hormone‐sensitive prostate carcinoma and that quality of life (QOL) steadily declines over the last year of life for men with prostate carcinoma. The primary purpose of the current study was to evaluate whether there was evidence of palliative effects associated with suramin at any of the three doses administered in the original clinical trial. 

Paper Mentions

Interventional Clinical Trial
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy… Expand
ConditionsProstate Cancer
InterventionDrug
Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature
TLDR
This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients’ quality of life, and provides a narrative description of the evolving role ofquality of life measures in clinical trials. Expand
Health related quality of life in NCI-sponsored cancer treatment trials.
TLDR
There has been an upsurge in the number and types of HRQOL measures used in phase III cancer treatment trials over the past 20 years and clinicians can use these data to help patients better understand the spectrum and severity of symptomatic toxicities they will experience with cancer treatment. Expand
Chemotherapy for hormone-refractory prostate cancer.
TLDR
The role of chemotherapy in men with metastatic prostate cancer is assessed to assess the effect of chemotherapy on pain relief, prostate-specific antigen (PSA) response, quality of life, and treatment-related toxicity. Expand
Effect of dose-intensive chemotherapy on quality of life
TLDR
egFR in patients with colorectal canceralysed EGFR and showed that although mutations in EGFR were rare, about 90% of those who showed objective responses to cetuximab had an increased number of gene copies of EGFR. Expand
Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.
TLDR
A wide variety of assessment tools and also efforts to standardize and harmonize patient-reported outcomes and pain assessment were identified, however, the specific needs of the increasing CRPC population living longer with their incurable cancer are insufficiently captured and objective physical outcome measures are under-represented. Expand
Quality of Life Assessment of Randomized Controlled Trials
TLDR
More attention to QOL in all components of RCCTs (design, choice of instruments, data management and processing) is required from both clinicians and statisticians. Expand
Physiology and Endocrinology of Hot Flashes in Prostate Cancer
TLDR
Research is needed to explore the physiological mechanisms of hot flashes to develop better therapeutic treatment options to ameliorate side effects of hormonal treatment and to integrate the available hormonal data into a hypothesis. Expand
Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis
TLDR
A systematic review and quantitative analysis of randomized clinical trials of patients with cancer failed to find a significant association between PFS and HRQoL in cancer clinical trials, raising questions regarding the assumption that interventions prolonging PFS also improve HRQeL in patients withcancer. Expand
Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials
TLDR
Data suggest the BPI pain intensity and FACT-P pain scales are better than the PPI question at capturing the pain experience among patients with advanced prostate cancer. Expand
How are palliative care cancer populations characterized in randomized controlled trials? A literature review.
TLDR
A substantial variation exists in how palliative care cancer populations are described in RCTs and few variables are consistently registered and reported, suggesting a clear need to standardize the reporting. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 24 REFERENCES
Health-related quality of life in men with prostate cancer.
TLDR
A structured MEDLINE review of literature on health related quality of life in prostate cancer for the years 1995 to 2001 was performed and was augmented with highly relevant articles from additional selected journals to familiarize the reader with the methodology ofquality of life research. Expand
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
TLDR
Treatment with mitoxantrone plusprednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone. Expand
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.
TLDR
Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change. Expand
Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG)
TLDR
The baseline QoL assessment of patients with prostate cancer who were randomised into three EORTC phase III studies found that the physical functioning, role functioning, global health/QoL scales and the single pain item scale from the E ORTC QLQ-C30 (version 1) are valid measures when used in the setting of prostate cancer. Expand
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
TLDR
Outpatient treatment with suramin plus HC is well tolerated and provides moderate palliative benefit and delay in disease progression for patients with symptomatic HRPC. Expand
Quality of life before death for men with prostate cancer: results from the CaPSURE database.
TLDR
Quality of life begins a steady and inexorable decline in thefinal 12 months of life in men with prostate cancer and increased attention to quality of life changes may provide new clinical opportunities to enhance quality of care in the final year of life. Expand
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
  • E. Small, S. Halabi, +9 authors N. Vogelzang
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
High-dose suramin was associated with higher objective and PSA response rates, but these were not statistically significant, and the lack of a dose-response relationship and the toxicity profile observed raise questions regarding the utility of suramin, particularly high-doseSuramin, as administered on this schedule. Expand
Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening
TLDR
Relatively small gains in HRQL have significant value, perhaps due to patients' tendency to minimize personal negative evaluations about one's condition, which has important implications for the interpretation of the meaningfulness of change scores inHRQL questionnaires. Expand
Drug treatment of cancer pain in a drug-oriented society
TLDR
The drug treatment of cancer pain in a drug oriented society is one book that the authors really recommend you to read, to get more solutions in solving this problem. Expand
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
TLDR
The development of a self‐report instrument designed to assess pain in cancer and other diseases and the evaluated Wisconsin Brief Pain Questionnaire suggest that the BPQ is sufficiently reliable and valid for research purposes. Expand
...
1
2
3
...